Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...
Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...
Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...
A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.
The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...
With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...
It’s not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisk’s diabetes ...